Compare Stocks → [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARCTNASDAQ:JANXNASDAQ:KNTENASDAQ:TSVTNASDAQ:VERA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$27.06+4.2%$34.63$17.52▼$43.81$728.46M2.6458,008 shs327,983 shsJANXJanux Therapeutics$48.88+0.4%$36.00$5.65▼$58.69$2.52B4.18759,005 shs1.12 million shsKNTEKinnate Biopharma$2.65-0.4%$2.57$1.04▼$7.18$125.13M1.38418,678 shs2.81 million shsTSVT2seventy bio$4.65+2.9%$5.18$1.53▼$12.69$238.60M1.841.39 million shs406,346 shsVERAVera Therapeutics$39.13+3.0%$43.54$6.07▼$50.78$2.13B1.051.30 million shs714,083 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+4.16%-7.68%-20.18%-21.86%-2.24%JANXJanux Therapeutics+0.39%-5.75%+23.65%+410.23%+217.20%KNTEKinnate Biopharma0.00%0.00%0.00%+8.16%-7.99%TSVT2seventy bio+2.88%-6.72%-9.36%+50.00%-45.68%VERAVera Therapeutics+2.97%-15.90%-4.56%+129.64%+499.23%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARCTArcturus Therapeutics1.6747 of 5 stars3.50.00.00.02.03.30.6JANXJanux Therapeutics2.6202 of 5 stars4.51.00.00.01.93.30.0KNTEKinnate Biopharma4.3118 of 5 stars3.05.00.04.70.03.31.3TSVT2seventy bio3.4515 of 5 stars4.21.00.00.03.33.31.3VERAVera Therapeutics0.5486 of 5 stars1.51.00.00.02.15.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics3.00Buy$61.33126.66% UpsideJANXJanux Therapeutics3.00Buy$61.3325.48% UpsideKNTEKinnate Biopharma2.00Hold$8.15207.45% UpsideTSVT2seventy bio2.38Hold$13.17183.15% UpsideVERAVera Therapeutics3.00Buy$32.29-17.49% DownsideCurrent Analyst RatingsLatest ARCT, KNTE, VERA, JANX, and TSVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024JANXJanux TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/8/2024TSVT2seventy bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $12.004/5/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$56.003/27/2024VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$27.00 ➝ $56.003/21/2024JANXJanux TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$62.003/21/2024VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$21.00 ➝ $34.003/20/2024ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/20/2024JANXJanux TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$100.003/18/2024TSVT2seventy bioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.003/13/2024JANXJanux TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $48.003/11/2024JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$53.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$169.93M4.29N/AN/A$10.42 per share2.60JANXJanux Therapeutics$8.08M312.40N/AN/A$7.46 per share6.55KNTEKinnate BiopharmaN/AN/AN/AN/A$5.06 per shareN/ATSVT2seventy bio$100.39M2.38N/AN/A$5.04 per share0.92VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$29.73M-$1.04N/A5.31N/A-15.65%-18.22%-11.95%5/14/2024 (Estimated)JANXJanux Therapeutics-$58.29M-$1.34N/AN/AN/A-721.18%-17.88%-15.95%5/14/2024 (Estimated)KNTEKinnate Biopharma-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%5/9/2024 (Estimated)TSVT2seventy bio-$217.57M-$4.42N/A66.43N/A-216.73%-59.19%-29.67%5/1/2024 (Estimated)VERAVera Therapeutics-$95.99M-$2.29N/AN/AN/AN/A-73.33%-50.79%5/9/2024 (Estimated)Latest ARCT, KNTE, VERA, JANX, and TSVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023VERAVera Therapeutics-$0.53-$0.58-$0.05-$0.58N/AN/A3/8/2024Q4 2023JANXJanux Therapeutics-$0.37-$0.25+$0.12-$0.25$0.98 million$2.46 million3/7/2024Q4 2023ARCTArcturus Therapeutics-$1.69-$0.32+$1.37-$0.32$64.14 million$33.99 million3/5/202412/31/2023TSVT2seventy bio-$1.22-$1.11+$0.11-$1.11$13.91 million$10.68 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AKNTEKinnate BiopharmaN/AN/AN/AN/AN/ATSVT2seventy bioN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A4.724.72JANXJanux TherapeuticsN/A26.8026.80KNTEKinnate BiopharmaN/A10.8010.80TSVT2seventy bioN/A3.983.98VERAVera Therapeutics0.497.717.71OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%JANXJanux Therapeutics75.39%KNTEKinnate Biopharma80.89%TSVT2seventy bio93.90%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics13.80%JANXJanux Therapeutics35.40%KNTEKinnate Biopharma41.70%TSVT2seventy bio2.60%VERAVera Therapeutics21.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18026.92 million23.20 millionOptionableJANXJanux Therapeutics6451.66 million33.37 millionOptionableKNTEKinnate Biopharma8447.22 million27.53 millionOptionableTSVT2seventy bio27451.31 million49.98 millionOptionableVERAVera Therapeutics5154.45 million42.64 millionOptionableARCT, KNTE, VERA, JANX, and TSVT HeadlinesSourceHeadlineVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Analystsamericanbankingnews.com - April 21 at 2:12 AMRusfertide Shows Promise in Polycythemia Verarenalandurologynews.com - April 17 at 10:25 PMVera Therapeutics (NASDAQ:VERA) Trading Down 3% on Insider Sellingamericanbankingnews.com - April 16 at 1:26 AMVera Therapeutics (NASDAQ:VERA) Shares Down 3% After Insider Sellingmarketbeat.com - April 15 at 10:35 AMVera Therapeutics executive sells over $228k in company stockinvesting.com - April 14 at 9:09 AMVera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells $228,560.00 in Stockamericanbankingnews.com - April 14 at 4:42 AMVanguard Group Inc. Raises Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)marketbeat.com - April 14 at 4:16 AMWhat about the company Vertex didn’t buy?statnews.com - April 13 at 7:39 PMInsider Selling: Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells 5,714 Shares of Stockinsidertrades.com - April 13 at 7:09 AMVera Therapeutics (NASDAQ:VERA) Sees Large Volume Increaseamericanbankingnews.com - April 13 at 5:58 AMCould This Stock Be the Next Biotech Buyout?fool.com - April 13 at 5:29 AMInsider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...finance.yahoo.com - April 12 at 10:56 PMJoseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stockmarketbeat.com - April 12 at 6:34 PMVertex wagers $4.9bn on Alpine kidney disease therapypharmaphorum.com - April 11 at 8:49 PMBiotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Optionsmsn.com - April 11 at 8:49 PM2 Biotech Stocks Driving the Nasdaq Todayschaeffersresearch.com - April 11 at 1:41 PMVera Therapeutics (NASDAQ:VERA) Stock Price Up 7.2%marketbeat.com - April 10 at 3:24 PMAlpine Immune jumps on report of takeover interestmsn.com - April 10 at 1:24 PMVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider Sellingmarketbeat.com - April 8 at 10:24 AMVera Therapeutics, Inc. (NASDAQ:VERA) CFO Sells $3,954,187.08 in Stockinsidertrades.com - April 8 at 4:24 AMPosttransplant Skin Disease: Consider Skin Cancer, Infection Risksmedscape.com - April 7 at 8:24 PMCommit To Buy Vera Therapeutics At $25, Earn 12.7% Annualized Using Optionsnasdaq.com - April 7 at 3:24 PMSean Grant Sells 99,828 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stockmarketbeat.com - April 6 at 12:37 AMGuggenheim Reiterates Buy Rating for Vera Therapeutics (NASDAQ:VERA)marketbeat.com - April 5 at 11:10 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesWhat's Driving Tesla Lower Ahead of its Earnings?April 18, 2024 8:45 AMView What's Driving Tesla Lower Ahead of its Earnings?5 Semiconductor Giants: Navigating the Recent PullbackApril 12, 2024 9:10 AMView 5 Semiconductor Giants: Navigating the Recent Pullback5 Small-Cap Energy Stocks Surged in Price and Volume on FridayApril 15, 2024 7:50 AMView 5 Small-Cap Energy Stocks Surged in Price and Volume on FridayGreen Gold Rush: Here's What's Driving Cannabis Stocks HigherApril 2, 2024 7:17 AMView Green Gold Rush: Here's What's Driving Cannabis Stocks HigherAll In: Is MicroStrategy Overleveraging Its Future on Bitcoin? March 26, 2024 6:05 AMView All In: Is MicroStrategy Overleveraging Its Future on Bitcoin? All Headlines Company DescriptionsArcturus TherapeuticsNASDAQ:ARCTArcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Janux TherapeuticsNASDAQ:JANXJanux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Kinnate BiopharmaNASDAQ:KNTEKinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.2seventy bioNASDAQ:TSVT2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Vera TherapeuticsNASDAQ:VERAVera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.